Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Genetic insights may explain retinal growth, eye cancer

10.05.2006
St. Jude investigators discover role of several key genes in retina development

Investigators at St. Jude Children’s Research Hospital have discovered the role of several key genes in the development of the retina, and in the process have taken a significant step toward understanding how to prevent or cure the potentially deadly eye cancer retinoblastoma. Retinoblastoma is the third most common cancer in infants after leukemia and neuroblastoma (nerve cancer). Retinoblastoma that has spread outside the eye is among the deadliest childhood cancers, with an average survival rate of less than 10 percent.

A key finding of the new study is that humans are more susceptible to developing retinoblastoma than mice, because mice can compensate for the loss of a gene critical to normal retinal development while humans cannot. The results of the study appear in the open-access journal BMC Biology.

"Our study gives us important new information on the normal development of the retina and suggests new studies that could lead to the design of more effective drugs to treat retinoblastoma," said Michael Dyer, Ph.D., an associate member of the Department of Developmental Neurobiology at St. Jude and senior author of the paper.

The researchers discovered that during the development of the retina in mice, three genes that belong to the Rb gene family are expressed at different times. Specifically, the p107 gene is active before birth in cells that are going to become the retina. This gene ensures that the retinal cells stop multiplying at the proper time during development of this tissue. The Rb gene is expressed after birth in those cells that are actively multiplying as they also help form the retina.

In addition, the St. Jude team found that when Rb was inactivated during development of the mouse retina, the two p107 gene copies were up-regulated--made more active--therefore compensating for this loss of Rb activity. Importantly, this compensation required the presence of both p107 genes. In turn, when p107 was inactivated, Rb activity was upregulated; but unlike with p107, this compensation required only one copy of Rb.

The St. Jude team proposes that the ability of Rb and p107 to compensate for the absence of each other in mice prevents the developing retinal cells from multiplying uncontrollably and causing retinoblastoma. Also, the expression of both Rb and p130 might prevent this cancer in mice.

However, researchers learned that conditions in humans are not the same as in mice. They found that the primary Rb gene family member active in the developing human retina is RB1, and unlike in the mouse, little p107 is expressed in the developing human retina. In addition, p107 is not up-regulated to compensate for a loss of RB1 activity.

"This could explain why humans are susceptible to retinoblastoma following RB1 gene mutations, while mice require inactivation of both Rb and p107, or both Rb and p130," said Dyer.

The discovery by the St. Jude team that p107 is not expressed during development of the retina in humans suggests that it might be possible in the future to prevent retinoblastoma by "turning on" that gene, Dyer noted.

"Because the eye is visible to researchers studying retinoblastoma, it’s possible to watch a tumor grow from a single cell," said Stacy Donovan, Ph.D., a postdoctoral fellow in Dyer’s laboratory. "This could tell us which type of cell in the developing eye causes this cancer."

"Knowing which cell causes retinoblastoma would give researchers a specific target for a novel retinoblastoma drug," added Brett Schweers, Ph.D. a postdoctoral fellow in Dyer’s laboratory at St. Jude. "The biochemical pathway driving the multiplication of a cancer cell of origin would differ, depending on whether it was a progenitor cell or one of the more specialized cells. So it would be important to know which type of cell is giving rise to the tumor. That way you could design a drug to knock out the pathway driving the abnormal growth in that particular cell."

Donovan and Schweers are the first and second authors respectively of the paper and contributed equally to the work.

Dyer’s team previously developed the first reliable mouse models of retinoblastoma that could be used to test new drug therapies for this tumor: http://www.stjude.org/media/0,2561,453_5485_11388,00.html.

Subsequently, the team used these models to demonstrate that a combination of topotecan and carboplatin were superior to the current treatment being used to treat retinoblastoma: http://www.stjude.org/developmental-neurobiology/0,2522,414_2041_19593,00.html.

Other authors of the paper include Rodrigo Martins of St. Jude and Dianna Johnson (University of Tennessee).

Bonnie Kourvelas | EurekAlert!
Further information:
http://www.stjude.org
http://www.stjude.org/media/0,2561,453_5485_11388,00.html
http://www.stjude.org/developmental-neurobiology/0,2522,414_2041_19593,00.html

More articles from Life Sciences:

nachricht Cancer diagnosis: no more needles?
25.05.2018 | Christian-Albrechts-Universität zu Kiel

nachricht Less is more? Gene switch for healthy aging found
25.05.2018 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>